Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Director | March 09, 2026 | March 12, 2026 |
| BIOGEN INC.BIIB · Entity 1675 | Chief Financial Officer | February 13, 2026 | February 18, 2026 |
| HERTZ GLOBAL HOLDINGS, INCHTZ · Entity 5147 | Sr VP Chief Accounting Officer | April 29, 2018 | May 01, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date March 09, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.61 · Expires 2036-03-09 | Direct | 25,640 |
Reported balance
After 2026-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-09 · Grant · Acquired 25,640 · Balance 25,640 F1: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.
BIOGEN INC.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 8,450 |
Reported balance
After 2026-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 8,450 · Balance 8,450 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
HERTZ GLOBAL HOLDINGS, INC
Report date April 29, 2018 · Filed May 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,062 |
Ending reported balance
After 2018-04-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-04-29 · Exercise / conversion · Acquired 798 · Balance 6,257 F1: Each Performance Stock Unit represents a contingent right to receive one share of HTZ common stock. The Performance Stock Units were initially granted in 2015 and the amount of Performance Stock Units eligible for vesting is subject to the satisfaction of performance goals for 2016 and 2017. These Performance Stock Units are eligible for vesting based on the satisfaction of the Customer Satisfaction metric, subject to continued employment on the applicable vesting date. Row 2 · 2018-04-29 · Tax withholding · Disposed 195 · Balance 6,062 F2: Shares withheld to pay tax liabilities incident to the vesting of Performance Stock Units. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-04-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-04-29 · Exercise / conversion · Disposed 798 · Balance 0 F1: Each Performance Stock Unit represents a contingent right to receive one share of HTZ common stock. The Performance Stock Units were initially granted in 2015 and the amount of Performance Stock Units eligible for vesting is subject to the satisfaction of performance goals for 2016 and 2017. These Performance Stock Units are eligible for vesting based on the satisfaction of the Customer Satisfaction metric, subject to continued employment on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Performance Stock Unit represents a contingent right to receive one share of HTZ common stock. The Performance Stock Units were initially granted in 2015 and the amount of Performance Stock Units eligible for vesting is subject to the satisfaction of performance goals for 2016 and 2017. These Performance Stock Units are eligible for vesting based on the satisfaction of the Customer Satisfaction metric, subject to continued employment on the applicable vesting date.
F2: Shares withheld to pay tax liabilities incident to the vesting of Performance Stock Units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2023 Filed Feb 22, 2023 22:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 512 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006519 · form4.xml · derivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,422 Underlying: Common Stock · 512 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 238 | $278.38 | $66,254.44 |
DisclosureSEC source: 0001127602-23-006519 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,331.7483 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 512 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006519 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,843.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:37 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 278 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005270 · form4.xml · derivative · entry 8 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 278 shares Expires 2023-02-12 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 228 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005270 · form4.xml · derivative · entry 7 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278 Underlying: Common Stock · 228 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 833 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005270 · form4.xml · derivative · entry 6 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Common Stock · 833 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 261 | $286.30 | $74,724.30 |
DisclosureSEC source: 0001127602-23-005270 · form4.xml · nonDerivative · entry 5 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,569.7483 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 27, 2023. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 67 | $286.30 | $19,182.10 |
DisclosureSEC source: 0001127602-23-005270 · form4.xml · nonDerivative · entry 4 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,830.7483 Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 228 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005270 · form4.xml · nonDerivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,897.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 262 | $286.30 | $75,010.60 |
DisclosureSEC source: 0001127602-23-005270 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,669.7483 Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 833 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005270 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,931.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:50 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 2,365 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004581 · form4.xml · derivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,365 Underlying: Common Stock · 2,365 shares Expires 2026-02-08 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 23:02 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 887 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002487 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,098.7483 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2020. The shares will vest on February 12, 2023. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 350 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-027340 · form4.xml · derivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 702 Underlying: Common Stock · 350 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing on the first anniversary of the grant date of 12/8/2021. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 156 | $289.10 | $45,099.60 |
DisclosureSEC source: 0001127602-22-027340 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,211.7483 Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 350 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-027340 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,367.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 252 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-019021 · form4.xml · derivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252 Underlying: Common Stock · 252 shares Expires 2023-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 07/01/2020. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 74 | $210.63 | $15,586.62 |
DisclosureSEC source: 0001127602-22-019021 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,017.7483 Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 252 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-019021 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,091.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 102.4003 shares acquired under the Biogen Inc. employee stock purchase plan. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 19:53 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001104659-22-046451 · tm2212851-6_4seq1.xml · derivative · entry 1 Kramer Robin · CIK 0001609222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2032-04-13 F1 · derivative.exercise_date: The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:18 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 570 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006271 · form4.xml · derivative · entry 4 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,934 Underlying: Common Stock · 570 shares Expires 2024-02-18 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 396 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006271 · form4.xml · derivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,504 Underlying: Common Stock · 396 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 117 | $209.79 | $24,545.43 |
DisclosureSEC source: 0001127602-22-006271 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,737.348 Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:18 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 396 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006271 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,854.348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:13 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 326 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004987 · form4.xml · derivative · entry 9 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506 Underlying: Common Stock · 326 shares Expires 2023-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 176 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004987 · form4.xml · derivative · entry 8 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 832 Underlying: Common Stock · 176 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:13 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 189 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004987 · form4.xml · derivative · entry 7 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189 shares Expires 2022-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 99 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004987 · form4.xml · derivative · entry 6 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189 Underlying: Common Stock · 99 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 85 | $214.59 | $18,240.15 |
DisclosureSEC source: 0001127602-22-004987 · form4.xml · nonDerivative · entry 5 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,458.348 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 21, 2022. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 51 | $214.59 | $10,944.09 |
DisclosureSEC source: 0001127602-22-004987 · form4.xml · nonDerivative · entry 4 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,543.348 Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 176 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004987 · form4.xml · nonDerivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,594.348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 35 | $214.59 | $7,510.65 |
DisclosureSEC source: 0001127602-22-004987 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,418.348 Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 99 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004987 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,453.348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:24 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004794 · form4.xml · derivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2025-02-10 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:46 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 244 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-001861 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354.348 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:10 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 1,052 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-030720 · form4.xml · derivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052 Underlying: Common Stock · 1,052 shares Expires 2024-12-08 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing on the first anniversary of the grant date of 12/8/2021. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 265 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-030462 · form4.xml · derivative · entry 7 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 265 shares Expires 2021-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:09 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 104 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-030462 · form4.xml · derivative · entry 6 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104 shares Expires 2021-12-03 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 74 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-030462 · form4.xml · derivative · entry 5 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104 Underlying: Common Stock · 74 shares Expires 2021-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 22 | $223.92 | $4,926.24 |
DisclosureSEC source: 0001127602-21-030462 · form4.xml · nonDerivative · entry 4 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,110.348 Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 78 | $223.92 | $17,465.76 |
DisclosureSEC source: 0001127602-21-030462 · form4.xml · nonDerivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,132.348 Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 265 | $223.92 | $59,338.80 |
DisclosureSEC source: 0001127602-21-030462 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,210.348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 74 | $223.92 | $16,570.08 |
DisclosureSEC source: 0001127602-21-030462 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 945.348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:34 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 251 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-021266 · form4.xml · derivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504 Underlying: Common Stock · 251 shares Expires 2023-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 07/01/2020. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:34 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 74 | $348.92 | $25,820.08 |
DisclosureSEC source: 0001127602-21-021266 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 871.348 F1 · balance_after: Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:34 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 251 | $348.92 | $87,578.92 |
DisclosureSEC source: 0001127602-21-021266 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 945.348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:25 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001104659-21-078786 · tm2119245-2_4seq1.xml · derivative · entry 1 Kramer Robin · CIK 0001609222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 2,900 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006986 · form4.xml · derivative · entry 1 Kramer Robin · CIK 0001609222 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,900 Underlying: Common Stock · 2,900 shares Expires 2024-02-18 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:59 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 289 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006274 · form4.xml · derivative · entry 8 Kramer Robin · CIK 0001609222 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008 Underlying: Common Stock · 289 shares Expires 2023-02-12 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 213 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006274 · form4.xml · derivative · entry 7 Kramer Robin · CIK 0001609222 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,297 Underlying: Common Stock · 213 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.